9 min read
Monthly FDA Guidance and Regulatory News Review - March 2026
March 2026 regulatory updates underscore newly published final and draft guidances focused on real-world data, safety...
We provide impactful strategies and solutions to meet your outsourcing needs in order to plan and run your next clinical trial, program or regulatory submission project. Our 25 years of experience helping emerging and small to mid-size biotech firms take their products from IND to NDA approval are worth taking a look at. In 2018 alone, our team prepared the regulatory submissions for 12% of the NMEs approved by the FDA. And, many of those programs we supported since the writing of the study protocols and IND.
Whether you have a compound and need to get started on your IND, or need to recruit patients quickly to get your early phase trials running or just need medical writing or biostatistical support for your programs - Veristat can help.
Speak with us at the Outsourcing in Clinical Trials West Coast conference in Burlingame, California on February 11-12, 2019! And, did you know, if you are a Director, VP or C-Suite member of a biotech, pharmaceutical or medical device firm, you can register for free.
Schedule a meeting by filling out the form on the right. Find out how we can help you advance your next clinical trial or regulatory submission to successful outcomes. Or, read some of our recent insightful perspectives.
9 min read
Apr 6, 2026 Veristat Blog
March 2026 regulatory updates underscore newly published final and draft guidances focused on real-world data, safety...
7 min read
Mar 27, 2026 Veristat Blog
In February 2026, FDA activity included new draft guidances, regulatory initiatives (e.g., PreCheck and eCTD 4.0),...